Add BrightSurf on Google Email

Novel immunotherapy demonstrates early potential to overcome resistance to immune checkpoint therapy

A Phase I study led by Timothy Yap demonstrates the potential of linavonkibart to target and prevent activation of transforming growth factor-beta 1 (TGFβ1), overcoming treatment resistance in multiple cancers. The trial showed manageable safety profiles and objective responses in heavily pre-treated patients, suggesting a promising ne...

SourceUniversity of Texas M. D. Anderson Cancer Center·JournalNature Medicine·TypeRandomized controlled/clinical trial·DateJan 13, 2026

Study: ADRIATIC clinical trial results suggest durvalumab may offer a new path in small cell lung cancer care

A new study suggests that durvalumab may offer a promising treatment option for limited-stage small cell lung cancer patients, extending overall and progression-free survival. However, the therapy's high cost poses significant challenges to sustainability and access in the real-world setting.

SourceUniversity of Miami Miller School of Medicine·JournalJCO Global Oncology·DateJan 9, 2026

Some antibodies outmaneuver germs from sticking to cells

Researchers discovered that certain antibodies employ unusual tactics to block bacterial adhesion, including creating molecular wedges and conformational traps. These mechanisms could lead to the development of immune therapies targeting glycan-binding cell-attachment proteins produced by bacteria causing urinary tract infections.

SourceUniversity of Washington School of Medicine/UW Medicine·JournalNature Communications·TypeExperimental study·DateJan 7, 2026

Large-scale study provides real-world data on rare side effect of cancer immunotherapy

A large-scale study identified risk factors and clinical features of ICI-ITP, a rare but serious complication of anti-cancer immunotherapy. The study found that patients with ICI-ITP tend to have lower platelet counts at the start of treatment, experience additional immune-related adverse events, and have a higher risk of death.

SourceMass General Brigham·JournalBlood·TypeObservational study·DateDec 12, 2025

Gut health à la CAR T

Researchers at Cold Spring Harbor Laboratory have devised a new approach to stimulate cell growth and repair in the intestine using CAR T-cell therapy. This therapy has shown promising results in improving gut health in both young and old mice, with significant reductions in inflammation and improved nutrient absorption.

SourceCold Spring Harbor Laboratory·JournalNature Aging·DateDec 11, 2025

Identification of an immuno-inflammatory biomarker in the brain supports potentially more effective personalized treatment for major psychiatric disorders

A study published in Biological Psychiatry identifies a distinct immuno-inflammatory biomarker in the brain linked to immune system dysfunction and poorer response to standard treatments. The findings provide potential value for clinical prediction and precision therapies.

SourceElsevier·JournalBiological Psychiatry·TypeImaging analysis·DateDec 11, 2025

Lower doses of immunotherapy for skin cancer give better results

A new study by researchers at Karolinska Institutet found that lower doses of approved immunotherapy drugs can give better results against tumours, while reducing side effects. The regimen with the lower dose of ipilimumab was more effective, with a higher proportion of patients responding to treatment and longer overall survival.

SourceKarolinska Institutet·JournalJNCI Journal of the National Cancer Institute·TypeObservational study·DateDec 7, 2025

Study: New protocol for Treg expansion uses targeted immunotherapy to reduce transplant complications

A new protocol for Treg expansion uses targeted immunotherapy to reduce transplant complications, boosting survival rates while preserving anti-cancer immunity. The protocol, led by Robert Levy, uses TL1A-Ig fusion protein and low-dose IL-2 to stimulate specific receptors on Tregs, promoting a safer environment for stem cell transplants.

Synergistic ferroptosis–immunotherapy nanoplatforms: Multidimensional engineering for tumor microenvironment remodeling and therapeutic optimization

Researchers have presented a comprehensive review on synergistic ferroptosis–immunotherapy nanoplatforms to overcome TME resistance and enhance antitumor immunity. The work offers a systematic roadmap for integrating ferroptosis induction with immunotherapy.

SourceShanghai Jiao Tong University Journal Center·JournalNano-Micro Letters·TypeExperimental study·DateNov 12, 2025

Nasal therapeutic vaccine for treating cervical cancer

Researchers at Chiba University have developed a nasal therapeutic vaccine targeting E7 oncoprotein, which is produced by high-risk strains of HPV associated with cervical cancer. The vaccine triggers an immune response in the cervical mucosa, providing local protection against pathogens and foreign particles.

SourceChiba University·JournalScience Translational Medicine·TypeExperimental study·DateNov 12, 2025

UCLA scientists develop one-product-fits-all immunotherapy for breast cancer

Researchers at UCLA have developed CAR-NKT cell therapy, which can attack tumors from multiple fronts while dismantling their protective shields. The therapy uses engineered immune cells that can be mass-produced from donated blood stem cells and stored ready-to-use, offering a potentially life-changing treatment option.

SourceUniversity of California - Los Angeles·JournalJournal of Hematology & Oncology·TypeExperimental study·DateOct 22, 2025

Targeted immunotherapy combination offers hope to older adults with leukemia

Researchers found a targeted immunotherapy regimen yielded promising survival outcomes for patients with B-cell ALL, outperforming historical results. The treatment was well-tolerated, with more than half completing the full course of therapy, and responded similarly in patients with complex medical histories.

SourceAlliance for Clinical Trials in Oncology·JournalJournal of Clinical Oncology·TypeRandomized controlled/clinical trial·DateOct 20, 2025

Survivors of high-risk neuroblastoma face substantial late effects of modern therapies

A study published in the Lancet Child and Adolescent Health journal found that high-risk neuroblastoma survivors experience a high prevalence of hearing loss, growth failure, underweight, and lung disease due to modern therapies. Longer follow-up periods were associated with a higher risk of late effects.

SourceAnn & Robert H. Lurie Children's Hospital of Chicago·JournalThe Lancet Child & Adolescent Health·DateOct 20, 2025

Repeated brain tumor sampling uncovers treatment response in patients with glioblastoma

A multi-institutional study found that serially testing tumor samples can detect immune system activation in recurrent glioblastoma even when traditional imaging measures cannot. The researchers used multi-omic analysis and integrated data from various sources to show positive changes in the tumor microenvironment over time.

SourceMass General Brigham·JournalScience Translational Medicine·TypeExperimental study·DateOct 8, 2025